Acquired Company
Hyperliquid Strategies completed a business combination with Sonnet BioTherapeutics Holdings, Inc. on 12/02/2025, after which Sonnet became a wholly-owned subsidiary of Hyperliquid.
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotech company, develops a platform for single-acting or bispecific biologics. The company is headquartered in Princeton, New Jersey. Show more
100 OVERLOOK CENTER, PRINCETON, NJ, UNITED STATES, 08540, Princeton, NJ, 08540, USA
Start AI Chat
Market Cap
8.603M
52 Wk Range
$1.08 - $10.38
Previous Close
$3.10
Open
$3.16
Volume
10,456,154
Day Range
$1.26 - $3.23
Enterprise Value
8.35M
Cash
321.3K
Avg Qtr Burn
-1.759M
Insider Ownership
4.25%
Institutional Own.
9.95%
Qtr Updated
06/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
SON-080 Details Chemotherapy-Induced Peripheral Neuropathy & Diabetic Peripheral Neuropathy (DPN) | Phase 2 Initiation | |
SON-1010 + Atezolizumab Details Platinum-resistant ovarian cancer | Phase 1/2 Update | |
SON-1210 w/ chemotherapeutic agents Details Advanced Solid Tumors & Pancreatic cancer | Phase 1/2 Update | |
SON-1010 (IL12-FHAB) +/- Trabectedin Details Leiomyosarcoma (LMS) or liposarcoma (LPS) | Phase 1 Update |
